• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Simponi (golimumab) - Articles and news items

Golimumab

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.

smc

SMC accepts five new medicines; rejects eculizumab

Industry news / 9 February 2016 / Victoria White

The committee was unable to accept eculizumab as it was “not considered to represent an effective use of NHS Scotland’s resources”…

simponi-msd

EC approves Simponi for the treatment of severe, active non-radiographic axial spondyloarthritis

Industry news / 26 June 2015 / Victoria White

The EC has approved Simponi (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA)…

eular

Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR

Industry news / 11 June 2015 / Victoria White

Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR…

spine-Simponi

CHMP adopts positive opinion of Simponi for the treatment of non-radiographic axial spondyloarthritis

Industry news / 26 May 2015 / Victoria White

CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis…

MSD Logo

New data at ACR meeting show efficacy of Simponi® (golimumab) in treating patients with active non-radiographic axial spondyloarthritis

Industry news / 19 November 2014 / MSD

Application for approval of new indication for golimumab has been filed with the European Medicines Agency…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +